Programme Category
Programme Name
Programme Description
IHI JU is based on the idea that interdisciplinary and cross-sector collaboration will enable perspective and breakthrough innovations in healthcare, including the pharmaceutical industry but also new fields such as biopharmaceuticals, medical technologies and biotechnologies.
Identifier Code
Call
Summary
To address this challenge, project(s) funded under this topic should aim at developing new, or innovative combinations of existing multi-modal theranostic solutions including radiopharmaceuticals and/or non- radioactive theranostic solutions. Applicants should clearly identify a disease(s) of unmet public health need, (e.g., oncology, neurology and/or advanced multi-disease conditions) and explain their choice with relevant evidence where possible.
This topic is focused on the development and proof of principle of new clinical applications of theranostics solutions.
Detailed Call Description
In particular, for the selected disease(s), the project(s) funded under this topic are expected to address all the following objectives:
- develop innovative theranostic solutions and consider conducting early phase clinical trial(s) as proof of concept(s) to demonstrate the added value of the proposed theranostic solutions for patients;
- develop tools for the quantification of the chosen disease(s) through the development of novel modalities to ensure proper planning and monitoring of patient care, which may include imaging, artificial intelligence and pathology models;
- facilitate the development of tools to increase European theranostic manufacturing capabilities and treatment capacities, including guidance on quality assurance and improving logistics of supply at the EU level;
- develop education and training materials on the deployment of multi-modal theranostic solutions and their integration in clinical settings including recommendations for the organisation and composition of disease-specific medical expert boards.
In addition, applicants are expected to consider the potential regulatory impact of the results and if relevant develop a strategy/plan for generating appropriate evidence as well as engaging with regulators in a timely manner (e.g., through the EMA Innovation Task Force, qualification/scientific advice).
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
Expected IHI contribution per project: €10 000 000 – €12 000 000
Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Researchers/Research Centers/Institutions
Eligibility For Participation Notes
For all the above topics applicant consortia should ensure that at least 45% of the action’s eligible costs and costs for action-related additional activities are provided by in-kind contributions to operational activities (IKOP), financial contributions (FC), or in-kind contributions to additional activities (IKAA) from private members and/or contributing partners and the constituent or affiliated entities of the private members and/or of the contributing partners. Contributing partners may not contribute IKAA.
Applicants should propose a project duration such that it matches project activities and expected outcomes and impacts.
Call Opening Date
Call Closing Date
EU Contact Point
All questions regarding JU JU invitations should be directed to infodesk@ihi.europa.eu.